Company news

Dimerix Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Chair address and CEO presentation to AGM

November 28, 2022

Dimerix Receives A$6.0M R&D Tax Incentive Rebate

October 24, 2022

Appendix 4E and 2022 Annual Report

August 28, 2022

CLARITY 2.0 COVID-19 Study Concludes Recruitment

August 17, 2022

New Patent Family Application for DMX-700

August 8, 2022

DMX-700 Study Shows Significant 80% Reduction in Lung Injury

July 3, 2022

REMAP-CAP COVID-19 Study Analysis Update

June 26, 2022

New Clinical Trial for DMX-200 in Diabetic Kidney Disease

June 6, 2022

Phase 3 FSGS Kidney Trial First Patient Recruited

May 30, 2022

Dimerix presentation at Bioshares Biotech Summit

May 11, 2022

FDA IND Approval for Phase 3 Study of DMX-200 in FSGS

May 8, 2022

Dimerix Receives A$3.7M R&D Tax Incentive Rebate

March 28, 2022

DSMB Change to REMAP-CAP COVID-19 Study

February 27, 2022

Half-Year Financial Report & Appendix 4D - 31 December 2021

February 23, 2022

First Regulatory Approval in Europe for DMX-200 FSGS Study

February 1, 2022

Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

January 10, 2022

Ethics Approval in Australia for Phase 3 COVID-19 Study

December 22, 2021

DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe

December 16, 2021

Pause in Trading

December 15, 2021

First Approvals Received for Start of Phase 3 FSGS Trial

October 20, 2021

Phase 3 DMX-200 COVID-19 Study Expands into Australia

October 14, 2021

Dimerix Closes SPP Oversubscribed

September 30, 2021

DMX-200 CLARITY COVID-19 Study Approval in India

September 24, 2021

Phase 3 Study in FSGS Kidney Patients Commences

August 24, 2021

SPP and Options Prospectus

August 23, 2021

Response to ASX Query

August 19, 2021

Successful $20m Placement to Fund Phase 3 Trials

August 15, 2021

DMX-200 COVID-19 Study Opens More Sites in Europe and UK

August 1, 2021

FDA Confirms Phase 3 Study Design in FSGS Kidney Disease

July 18, 2021

Dimerix Receives Innovation Passport and ILAP Designation

June 6, 2021

Dimerix Confirms Phase 3 FSGS Study Design With EMA

June 3, 2021

DMX-200 Remains Eligible for Accelerated Approval

May 27, 2021

COVID-19 Study Recruits Multiple Patients in Europe

April 22, 2021

Major Shareholder Loan for $5 Million

March 29, 2021

Clinical Study in Patients with COVID-19 Progresses

March 24, 2021

DMX-200 Competitive Position Further Enhanced

March 23, 2021

CLARITY 2.0 Study Progresses In Patients With COVID-19

March 9, 2021

Appendix 4D and Interim Financial Report

February 21, 2021

Dimerix Plans for Next Study in Diabetic Kidney Disease

January 27, 2021

Second Study to Include DMX-200 in COVID-19 Patients

November 29, 2020

ARDS in COVID-19 Patients Protocol Published

November 8, 2020

Positive Additional Data to Support DMX-200 Development

October 26, 2020

Receipt of R&D Tax Incentive

October 20, 2020

DMX-700 Data Demonstrates Effect on Key COPD Receptors

October 6, 2020

Positive Top-Line Results in DKD Phase 2 Clinical Study

September 13, 2020

Dimerix Awarded $1 Million MRFF Funding

September 2, 2020

Positive Top-Line Results in FSGS Phase 2a Clinical Study

July 28, 2020

Last Patient Completes Dosing in DKD Phase 2 Clinical Study

July 23, 2020

Dimerix Completes $5.8m Placement

June 22, 2020

Last Patient Completes Dosing in FSGS Phase 2 Clinical Study

June 16, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 86 decks. Every deck is listed under its year.